Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

Jan-Paul Gundlach

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8845-6832; OpenAlex author ID A5084133801. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119257↗
  2. Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities. Co-author DOI 10.3390/cancers16040686↗
  3. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-022-05535-9↗
  4. Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression. Co-author DOI 10.1007/s00432-021-03745-w↗
  5. The Hepatic Microenvironment and TRAIL-R2 Impact Outgrowth of Liver Metastases in Pancreatic Cancer after Surgical Resection. Co-author DOI 10.3390/cancers11060745↗
  6. NF-κB Dependent Chemokine Signaling in Pancreatic Cancer. Co-author DOI 10.3390/cancers11101445↗
  7. Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. Co-author DOI 10.1186/s12885-018-4688-8↗
  8. Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. Co-author DOI 10.18632/oncotarget.25884↗
  9. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1368603↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph Röcken · 5 shared papers, 2017–2026 · strength 0.66
  2. Susanne Sebens · 5 shared papers, 2017–2026 · strength 0.62
  3. Anne‐Sophie Mehdorn · 2 shared papers, 2024–2026 · strength 0.42
  4. H. Schäfer · 3 shared papers, 2017–2023 · strength 0.33
  5. Günter Schneider · 3 shared papers, 2017–2023 · strength 0.33
  6. Anna Trauzold · 3 shared papers, 2018–2021 · strength 0.29
  7. Alexander Arlt · 2 shared papers, 2019–2023 · strength 0.27
  8. Claudia Geismann · 2 shared papers, 2019–2023 · strength 0.27
  9. Hendrike Knaack · 2 shared papers, 2018–2024 · strength 0.25
  10. Lisa-Marie Philipp · 2 shared papers, 2018–2024 · strength 0.25
  11. Udo Schumacher · 2 shared papers, 2018–2024 · strength 0.25
  12. Daniela Wesch · 1 shared paper, 2026 · strength 0.24
  13. Rüdiger Braun · 1 shared paper, 2026 · strength 0.24
  14. Rainer Lothar Heuchel · 1 shared paper, 2026 · strength 0.24
  15. Anna Maxi Wandmacher · 1 shared paper, 2026 · strength 0.24
  16. Annika Bräuer · 1 shared paper, 2026 · strength 0.24
  17. Lennart Lenk · 3 shared papers, 2017–2019 · strength 0.21
  18. Christian Röder · 2 shared papers, 2018–2021 · strength 0.20
  19. Holger Kalthoff · 2 shared papers, 2018–2021 · strength 0.20
  20. Christian Schneeweis · 1 shared paper, 2023 · strength 0.17
  21. Sascha Rahn · 2 shared papers, 2018–2019 · strength 0.15
  22. Lauritz Miarka · 2 shared papers, 2018–2019 · strength 0.15
  23. Ole Helm · 2 shared papers, 2017–2019 · strength 0.14
  24. Silje Beckinger · 1 shared paper, 2019 · strength 0.09
  25. Maren Pein · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.